Covalon Technologies 8/16/2023 Earnings Report

Covalon Technologies EPS Results

• Actual EPS: -$0.02
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Covalon Technologies Revenue Results

• Actual Revenue: $4.67 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Covalon Technologies Announcement Details

• Date: 8/16/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Covalon Technologies (OTCMKTS:CVALF) (OTCMKTS:CVALF) is a Canadian life sciences company specializing in the development and commercialization of infection prevention and wound care technologies. The company’s core competencies lie in advanced antimicrobial coatings, biocompatible wound dressings and medical device technologies designed to reduce the risk of infection in surgical and acute care settings. Covalon’s product pipeline includes implantable antimicrobial coatings for orthopaedic and reconstructive devices, transparent wound care dressings that deliver targeted antimicrobial agents, and advanced catheter coatings engineered to combat central line–associated bloodstream infections.

Founded in 2001 and headquartered in Vancouver, British Columbia, Covalon has expanded its global footprint with commercial operations across North America, Europe and select markets in Asia. The company leverages a network of distributors and strategic partnerships to bring its proprietary technologies into hospitals, clinics and specialty care centers. Its manufacturing facilities conform to ISO 13485 standards, and its regulatory clearances span Health Canada, the U.S. Food and Drug Administration and the European CE marking process.

Under the guidance of an executive team with extensive expertise in biomedical engineering, regulatory affairs and medical device commercialization, Covalon continues to advance its research programs and pursue opportunities in emerging wound care markets. The leadership’s focus on strategic collaborations and intellectual property development positions the company to address unmet clinical needs and to drive long-term growth in infection prevention and wound management sectors.